Dr Ajibola is a trained physician with a Master’s in Public Health and over 10 years experience in clinical research at Botswana Harvard Health Partnership (BHP). His research focuses on maternal-child health. He is Co-Investigator and Study Coordinator/ Physician for the Early Infant Treatment Study (EIT) and the follow-up Tatelo study entitled “A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies (bNAbs) VRC01LS and 10- 1074 on Maintenance of HIV Viral Suppression in a Cohort of Early-Treated Children in Botswana”. While working on these projects, he has developed several sub-studies including one that investigated the prevalence of antiretroviral drug resistance mutations among HIV- infected women following cessation of triple ARV prophylaxis used for preventing mother- to-child HIV transmission in Botswana and this presented him with his first opportunity to function as a Principal Investigator. Building logically on his prior work, and expertise, he was awarded an early-stage investigator grant by the EDCTP for his proposal to evaluate the risk of HIV acquisition among infants born preterm to women living with HIV and to quantify haematological toxicities of antiretroviral prophylaxis in preterm infants compared to infants born full-term. Dr Ajibola has served as a study physician routinely performing clinical evaluations on mothers and infants enrolled in both observational and interventional clinical trials and has authored and co-authored several publications.